- Home
- GMAB vs DECK Comparison
GMAB vs DECK Comparison
Compare GMAB & DECK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- DECK
- Stock Information
- Founded
- GMAB 1999
- DECK 1973
- Country
- GMAB Denmark
- DECK United States
- Employees
- GMAB N/A
- DECK N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- DECK Shoe Manufacturing
- Sector
- GMAB Health Care
- DECK Consumer Discretionary
- Exchange
- GMAB Nasdaq
- DECK Nasdaq
- Market Cap
- GMAB 17.4B
- DECK 14.1B
- IPO Year
- GMAB N/A
- DECK 1993
- Fundamental
- Price
- GMAB $30.42
- DECK $82.66
- Analyst Decision
- GMAB Strong Buy
- DECK Buy
- Analyst Count
- GMAB 6
- DECK 21
- Target Price
- GMAB $40.40
- DECK $122.16
- AVG Volume (30 Days)
- GMAB 2.4M
- DECK 5.6M
- Earning Date
- GMAB 11-06-2025
- DECK 10-23-2025
- Dividend Yield
- GMAB N/A
- DECK N/A
- EPS Growth
- GMAB 132.41
- DECK 18.83
- EPS
- GMAB 25.10
- DECK 6.75
- Revenue
- GMAB $3,845,670,022.00
- DECK $5,244,323,000.00
- Revenue This Year
- GMAB $24.92
- DECK $9.84
- Revenue Next Year
- GMAB $15.97
- DECK $7.36
- P/E Ratio
- GMAB $11.82
- DECK $12.27
- Revenue Growth
- GMAB 29.57
- DECK 12.62
- 52 Week Low
- GMAB $17.24
- DECK $78.91
- 52 Week High
- GMAB $33.65
- DECK $223.98
- Technical
- Relative Strength Index (RSI)
- GMAB 56.40
- DECK 38.76
- Support Level
- GMAB $28.08
- DECK $79.07
- Resistance Level
- GMAB $30.78
- DECK $86.69
- Average True Range (ATR)
- GMAB 0.68
- DECK 2.74
- MACD
- GMAB 0.10
- DECK 0.64
- Stochastic Oscillator
- GMAB 84.63
- DECK 32.49
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About DECK Deckers Outdoor Corporation
Founded in 1973, California-based Deckers designs and sells casual and performance footwear, apparel, and accessories. In fiscal 2025, Ugg and Hoka accounted for 51% and 45% of total sales, respectively. The firm also markets niche brands Teva and Ahnu. Deckers produces most of its sales through wholesale partnerships but also operates e-commerce in more than 50 countries and about 180 company-operated stores. It generated 64% of its fiscal 2025 sales in the United States.